Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Boehringer Ingelheim
AstraZeneca
McKesson
Baxter

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SINGULAIR

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Singulair

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00115297 Montelukast for Early Life Wheezing Active, not recruiting National Heart, Lung, and Blood Institute (NHLBI) Phase 2/Phase 3 2004-09-01 This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study.
NCT00115297 Montelukast for Early Life Wheezing Active, not recruiting University of Massachusetts, Worcester Phase 2/Phase 3 2004-09-01 This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study.
NCT00119015 The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis Terminated Merck Sharp & Dohme Corp. Phase 4 2005-07-01 Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
NCT00119015 The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis Terminated University of Chicago Phase 4 2005-07-01 Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
NCT00162864 A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease Completed Merck Sharp & Dohme Corp. Phase 3 1999-12-01 This randomized, double-blind, placebo-controlled trial assessed the efficacy of montelukast in the treatment of adults ≥50 years of age with persistent asthma and/or COPD. Primary outcomes included forced expiratory volume in one-second (FEV1) and daytime asthma symptoms scores. Nocturnal symptoms, asthma control, health-related quality of life, peak flow measurements, and health care utilization were also assessed as secondary outcomes. Participants were recruited from the Kaiser Permanente Northwest member population. One hundred forty-nine subjects were randomized to treatment with montelukast (10 mg per day) or placebo, and were followed for a six-week period. No differences in lung function measures, health-related quality of life, health care utilization, and asthma symptom scores were observed; however, the montelukast group had slightly improved asthma control scores compared to the placebo group.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Singulair

Condition Name

Condition Name for Singulair
Intervention Trials
Asthma 40
Healthy 14
Eosinophilic Esophagitis 3
Bronchiolitis Obliterans 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Singulair
Intervention Trials
Asthma 30
Rhinitis 11
Rhinitis, Allergic 9
Lung Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Singulair

Trials by Country

Trials by Country for Singulair
Location Trials
United States 90
India 10
United Kingdom 7
Canada 5
Korea, Republic of 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Singulair
Location Trials
North Carolina 5
New Jersey 4
Colorado 4
Ohio 4
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Singulair

Clinical Trial Phase

Clinical Trial Phase for Singulair
Clinical Trial Phase Trials
Phase 4 29
Phase 3 8
Phase 2/Phase 3 1
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Singulair
Clinical Trial Phase Trials
Completed 64
Unknown status 10
Active, not recruiting 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Singulair

Sponsor Name

Sponsor Name for Singulair
Sponsor Trials
Merck Sharp & Dohme Corp. 22
Dr. Reddy's Laboratories Limited 6
GlaxoSmithKline 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Singulair
Sponsor Trials
Other 61
Industry 60
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Baxter
Johnson and Johnson
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.